• AAPL 167.04
  • TSLA 149.9
  • AMZN 179.17
  • MSFT 404.33
  • INTC 35.04
  • EURUSD 1.0646
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. NXSCF.PINK

Next Science Limited (NXSCF PINK) stock market data APIs

$0.25 0(0%) as of April 17, 2024

Next Science Limited Financial Data Overview

0.25
0.25
-
0.25
0.25
0.116-0.51
77 622 K
292 M
22 179 K
-0.0107
1.044
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NXSCF',
Type: 'Common Stock',
Name: 'Next Science Limited',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00P53P4S6',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
HomeCategory: NULL,
IsDelisted: false,
}

Next Science Limited Fundamental Data is available in our Financial Data APIs

  • Net Revenue 22 179 K
  • EBITDA -15 438 462
  • Earnings Per Share -0.07
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Next Science Limited Earnings via APIs

  • Latest Release 2021-06-30
  • EPS/Forecast 0

Get Next Science Limited End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Next Science Limited latest news via APIs

Investors in Next Science (ASX:NXS) have unfortunately lost 78% over the last three years

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So consider, for a moment, the misfortune of Next Science Limited (ASX:N...
  • NEXT SCIENCE LIMITED
  • REVENUE GROWTH
  • SHARE PRICE

New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against Both Planktonic Bacteria and Bacterial Biofilms

Highlights In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria) XPER...
  • BIOFILM BACTERIA
  • BIOFILM FORMATION
  • JOURNAL OF ARTHROPLASTY
  • NEXT SCIENCE LIMITED
  • PJI
  • PLANKTONIC BACTERIA
  • TOTAL HIP ARTHROPLASTY
  • TOTAL KNEE ARTHROPLASTY
  • XPERIENCE
Do you have any questions?
support@eodhistoricaldata.com